Satoshi Suda1, Yasuyuki Iguchi2, Shigeru Fujimoto3, Yoshiki Yagita4, Yu Kono5, Masayuki Ueda6, Kenichi Todo7, Tomoyuki Kono7, Takayuki Mizunari8, Mineo Yamazaki9, Takao Kanzawa10, Seiji Okubo11, Kimito Kondo12, Nobuhito Nakajima13, Takeshi Inoue14, Takeshi Iwanaga15, Makoto Nakajima16, Ichiro Imafuku17, Kensaku Shibazaki18, Masahiro Mishina19, Koji Adachi20, Koichi Nomura21, Masataka Nakajima22, Hiroshi Yaguchi23, Sadahisa Okamoto24, Masato Osaki25, Yuka Terasawa26, Takehiko Nagao27, Kazumi Kimura28. 1. Department of Neurology, Nippon Medical School, Tokyo, Japan. Electronic address: suda-sa@nms.ac.jp. 2. Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan. 3. Division of Neurology, Department of Medicine, Jichi Medical University Hospital, Tochigi, Japan. 4. Department of Stroke Medicine, Kawasaki Medical School, Okayama, Japan. 5. Department of Neurology, Fuji City General Hospital, Shizuoka, Japan. 6. Department of Neurology and Stroke Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. 7. Department of Neurology, Kobe City Medical Center General Hospital, Hyogo, Japan. 8. Department of Neurosurgery, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan. 9. Department of Neurology, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan. 10. Department of Stroke Medicine, Institute of Brain and Blood Vessels, Mihara Memorial Hospital, Gunma, Japan. 11. Department of Cerebrovascular Medicine, NTT Medical Center Tokyo, Tokyo, Japan. 12. Department of Neurology, Hokuto Hospital, Hokkaido, Japan. 13. Department of Neurology, Kitamurayama Hospital, Yamagata, Japan. 14. Department of Stroke Medicine, Kawasaki Medical School General Medical Center, Okayama, Japan. 15. Department of Stroke Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan. 16. Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. 17. Department of Neurology, Yokohama Rosai Hospital, Kanagawa, Japan. 18. Department of Stroke Medicine, Kurashiki Heisei Hospital, Okayama, Japan. 19. Department of Neuro-pathophysiological Imaging, Graduate School of Medicine, Nippon Medical School, Kanagawa, Japan. 20. Department of Neurological Surgery, Nippon Medical School Musashi-Kosugi Hospital, Kanagawa, Japan. 21. Department of Neurology, Shioda Hospital, Chiba, Japan. 22. Department of Neurology, Heisei-Tateishi Hospital, Tokyo, Japan. 23. Department of Neurology, The Jikei University Kashiwa Hospital, Japan. 24. Department of Neurology, Omuta Tenryo Hospital, Fukuoka, Japan. 25. Department of Cerebrovascular Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan. 26. Department of Neurology, Brain Attack Center Ota Memorial Hospital, Hiroshima, Japan. 27. Department of Neurology, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan. 28. Department of Neurology, Nippon Medical School, Tokyo, Japan.
Abstract
OBJECTIVES: The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited. DESIGN: The prospective analysis of stroke patients taking anticoagulants (PASTA) registry study is an observational, multicenter, prospective registry of stroke (ischemic stroke, transient ischemic attack, and intracerebral hemorrhage) patients receiving OAC in Japan. This study is designed to collect data on clinical background characteristics, drug adherence, drug dosage, neurological severity at admission and discharge, infarct or hematoma size, acute therapy including recanalization therapy or reverse drug therapy, and timing of OAC re-initiation. Patient enrollment started in April 2016 and the target patient number is 1000 patients. CONCLUSIONS: The PASTA prospective registry should identify the status of stroke patients taking OAC in the current clinical practice in Japan.
OBJECTIVES: The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited. DESIGN: The prospective analysis of strokepatients taking anticoagulants (PASTA) registry study is an observational, multicenter, prospective registry of stroke (ischemic stroke, transient ischemic attack, and intracerebral hemorrhage) patients receiving OAC in Japan. This study is designed to collect data on clinical background characteristics, drug adherence, drug dosage, neurological severity at admission and discharge, infarct or hematoma size, acute therapy including recanalization therapy or reverse drug therapy, and timing of OAC re-initiation. Patient enrollment started in April 2016 and the target patient number is 1000 patients. CONCLUSIONS: The PASTA prospective registry should identify the status of strokepatients taking OAC in the current clinical practice in Japan.